- Home
- HLP vs MNOV Comparison
HLP vs MNOV Comparison
Compare HLP & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HLP | MNOV |
|---|---|---|
| Founded | 2021 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 69.4M |
| IPO Year | 2021 | 2004 |
Fundamental Metrics
Financial Performance| Metric | HLP | MNOV |
|---|---|---|
| Price | $0.43 | $1.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 622.2K | 31.7K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $180.00 |
| P/E Ratio | $51.63 | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $0.34 | $1.17 |
| 52 Week High | $1.72 | $1.96 |
Technical Indicators
Market Signals| Indicator | HLP | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 32.92 | 48.89 |
| Support Level | $0.38 | $1.30 |
| Resistance Level | $1.16 | $1.54 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 14.26 | 70.00 |
Price Performance
Historical ComparisonAbout HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.